paper spotlight Archives

Oncotarget News

Pitfalls of FDA-Approved Germline Cancer Predisposition Tests

December 30, 2024

The FDA approval on September 29, 2023, for 'class III de novo' blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct... read more

Oncotarget

CT Radiomics and Body Composition for Predicting Hepatic Decompensation

December 9, 2024

This study reveals the potential for prognostic features in predicting hepatic decompensation in patients with PSC.”BUFFALO, NY - December 9, 2024 – A new research paper was published in Oncotarget's Volume... read more

Oncotarget

Mesenchymal Stem Cells in Cancer Immunotherapy: Promises and Challenges

December 3, 2024

MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing abilities, and potential as carriers for delivering therapeutic agents.”BUFFALO, NY - December 3,... read more

Oncotarget

Visualizing Radiological Data Bias with Persistence Images

November 25, 2024

Persistence images represent a powerful new tool in our ongoing efforts to visualize, understand, and mitigate biases in radiological data interpretation and AI model development.”BUFFALO, NY - November 25, 2024 –... read more

Oncotarget

Reducing Bias in Radiology with Topological Data Analysis

November 18, 2024

By providing a more comprehensive, robust, and interpretable framework for analyzing medical imaging data, TDA has the potential to enhance the accuracy and fairness of radiological assessments.”BUFFALO, NY - November... read more

Oncotarget

Navigating Bias in AI-Driven Cancer Detection

November 11, 2024

As we eagerly adopt Al models, we need to take a moment to think about the potential biases that they may contain.”BUFFALO, NY - November 11, 2024 – A new editorial... read more

Oncotarget

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”BUFFALO,... read more

Oncotarget

Complete Response to Encorafenib + Binimetinib in BRAF V600E-Mutant Tumor

October 29, 2024

This case report highlights the importance of full tumor genotyping to identify potentially actionable targets in rare tumors such as malignant glomus tumors.”BUFFALO, NY- October 29, 2024 – A new... read more

Oncotarget

Next-Gen Cell-Penetrating Antibodies for Tumor Targeting and RAD51 Inhibition

October 21, 2024

Overall, the data presented in this study affirm that humanizing 3E10 preserves its crucial biological properties essential for therapeutic efficacy.”BUFFALO, NY- October 21, 2024 – A new research paper was... read more

Oncotarget

TP53 Mutated AML: Transplant or No Transplant

October 11, 2024

In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.”BUFFALO, NY- October 11, 2024 – A new editorial was published in... read more